NCT02856555

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of firsocostat in adults with nonalcoholic steatohepatitis (NASH).

Conditions

• Nonalcoholic Steatohepatitis (NASH)

Interventions

Type	Name	Description
DRUG	Firsocostat	Capsules orally once daily.
DRUG	Placebo	Placebo matched to firsocostat orally once daily.

Timeline

• Start date: 2016-08-08
• Primary completion: 2017-07-18
• Completion: 2017-07-18
• First posted: 2016-08-05
• Last updated: 2020-07-24
• Results posted: 2020-07-24

Locations

36 sites across 1 country: United States

Regulatory

• FDA-regulated drug study